Buccal Drug Delivery System Market Size to Gain USD 6.31 Billion By 2030, According to Polaris Market Research

Buccal Drug Delivery System Market Size to Gain USD 6.31 Billion By 2030, According to Polaris Market Research
According to the research report, the global buccal drug delivery system market size & share was valued at USD 2.86 Billion in 2021 and is expected to reach over USD 6.31 Billion By 2030, to grow at a CAGR of 9.6% during the forecast period.

According to the research report, the global buccal drug delivery system market size & share was valued at USD 2.86 Billion in 2021 and is expected to reach over USD 6.31 Billion By 2030, to grow at a CAGR of 9.6% during the forecast period.

Buccal drug delivery is the drug application through the mucosal membranes lining the cheeks. The excellent transport and absorption of drugs in the body is an optimal fragment of therapy. Preorally, drug administration is uncomplicated, conventional, and familiar, but from time to time, optional routes are needed. The prominent hindrances of the drug delivery method are substantial pre-systematic degeneration procedures in the liver or gut, bringing about insufficient or inconsistent absorption and low systematic bioavailability. The parenteral way is the only accepted means which conquer these hitches. It may not obtain the sustenance of sufficient blood level at the receptor for optimum utilization.

Buccal mucosa permits drug delivery for both systematic and local therapies. Local distribution to oval cavity tissues has numerous applications, involving curing local circumstances like periodontal illnesses, fungal and bacterial infections, aphthous stomatitis, and vesiculobullous diseases. When drugs are methodically put into buccal mucosa, many disadvantages linked with the peroral route are prohibited. The drug straightaway is stopped as it is directly pushed through systematic circulation, which keeps away from the hepatic first-pass metabolism and leads to higher bioavailability.

Request Sample Copy of the Buccal Drug Delivery System Market Research Report @ https://www.polarismarketresearch.com/industry-analysis/buccal-drug-delivery-system-market/request-for-sample

(The sample of this report is readily available on request. The report sample contains a brief introduction to the research report, Table of Contents, Graphical introduction of regional analysis, Top players in the market with their revenue analysis, and our research methodology.)

Important Questions Being Answered by the Market Report

  • What is the market size and growth?
  • What are the novel opportunities?
  • What is the buccal drug delivery market share?
  • What are the targeted audiences?
  • Who are the top players in the buccal drug delivery market?
  • What is the nature of competition in the future?
  • Which are the leading countries?
  • What is the impact of covid-19 and how to sustain in these markets that are fast evolving?

 

Top Market Players Are:

  • Applied Pharma Research
  • ARDEA BIOSCIENCES LIMITED
  • ARx LLC
  • AstraZeneca
  • Bayer AG
  • BioDelivery Sciences International Inc.
  • Catalent
  • Cynapsus Therapeutics Inc.
  • Dr. Reddy’s Laboratories Ltd
  • Endo Pharmaceuticals plc
  • F. Hoffmann-La Roche Ltd
  • Generex Biotechnology
  • GlaxoSmithKline plc
  • Indivior PLC
  • MedLab
  • NAPP PHARMACEUTICALS LIMITED
  • Novartis AG
  • Novo Nordisk A/S
  • Pfizer Inc.
  • Sanofi
  • Takeda Pharmaceutical Company Limited.
  • Teva Pharmaceutical Industries Ltd

 

Request for Discount on Buccal Drug Delivery System Market Report Before Purchase @ https://www.polarismarketresearch.com/industry-analysis/buccal-drug-delivery-system-market/request-for-discount-pricing

Buccal drug delivery market: Growth leading factors

Buccal drug delivery has gained outstanding growth because of ongoing research and development. Compared to oral dosage disposition, buccal delivery is regarded as the most preferred and convenient choice, particularly among elderly patients. The drug delivery route guarantees eradication of first-pass metabolism permitting drugs that are sensitive to PH and debased to be applied constructively. Speedy absorption, lessened biofluid interconnection, decreased side effects, growing focus ability at the target site, and shorter treatment regime are responsible for the increased buccal drug delivery acquisition.

The growing preference of patients from traditional drugs, disregarding obtaining of progressive drug administration, is driving the market. The development of advanced medicinal remedies is available to benefits offered by devices like auto-injectors, wearables, and dry powder inhalers and alternatives over traditional drug dispensing forms like injections. Progressed medicine delivery offer drug dispensing that is needle-free and thus highly preferred amongst patients. These devices are intelligent, portable, and provide the user a higher amount of flexibility and the benefits of self-administration and self-monitoring attributes.

Despite significant investments and research to advance a formulation that is new, due to the covid-19 pandemic, there was a dramatic reduction in the market. Stopping supply logistics, decreased raw material availability, reduced laboratory staff to execute new research, the economic burden on end-users, and the lesser need for buccal delivery medication led to a gap in the market.

Directly Purchase a copy of the report with TOC @ https://www.polarismarketresearch.com/checkouts/12341

Global Buccal Drug Delivery Market: Report Scope

Report Attribute

Details

Market Size 2021 Value

USD 2.86 Billion

Market Outlook for 2030

USD 6.31 Billion

Expected CAGR Growth

9.6% from 2022 – 2030

Base year

2020

Forecast period

2022 – 2030

Segments covered

By Type, By Application, By End-Use, By Region

Key Companies

Applied Pharma Research, ARDEA BIOSCIENCES LIMITED, ARx LLC, AstraZeneca, Bayer AG, BioDelivery Sciences International, Inc., Catalent, Cynapsus Therapeutics Inc., Dr. Reddy’s Laboratories Ltd, Endo Pharmaceuticals plc, F. Hoffmann-La Roche Ltd, Generex Biotechnology, GlaxoSmithKline plc, Indivior PLC, MedLab, NAPP PHARMACEUTICALS LIMITED, Novartis AG, Novo Nordisk A/S, Pfizer Inc., Sanofi, Takeda Pharmaceutical Company Limited., and Teva Pharmaceutical Industries Ltd

Regional scope

North America, Europe, Asia Pacific, Latin America, Middle East & Africa

Customization Options

Customized purchase options are available to meet your research needs.

 

Buccal drug delivery market: Key segmentation

  • Insight by type, application, end-use, and region

 

By type, the buccal tablets and lozenges dominated the market. Growing consumer acceptance, cost-effectiveness, simplified formulations, and broad obtainability of drug contenders for formulation are the elements accountable for the growth of the segment. By application, smoking termination dominated the market. Buccal drug delivery is usually the most favored and efficacious formulation for curing patients with addiction to nicotine and smoking. By end-use, the hospital segment ruled the market owing to growing hospital admission, particularly the elderly patients, plenty of emergency car supplies, and product advancement and research by different community hospitals.

By region, North America dominated the market due to the presence of a vast number of market players, enhanced research to recognize appropriate drug contenders, special financing by prominent players to improvise the advancement of newer formulations, and enhanced percentage of treatment and diagnosis are some of the factors are anticipated to influence the market growth in the region. The Asia Pacific is also expected to monitor the highest growth. The development of the elderly population and pharmaceutical industries and an extensive rise in the domestic players will boost the regional market growth. The region includes a vast population of the elderly who are susceptible to many lifestyles linked to cardiovascular conditions. There is the growth of the market in this region.

Browse the full “Buccal Drug Delivery System Market Share, Size, Trends, Industry Analysis Report, By Type (Sublingual Films, Buccal Tablets, and Lozenges, Oral Sprays); By Application (Pain Management, Smoking Cessation, Angina Pectoris, Others); By End-Use (Hospitals, Ambulatory Centers, Others), By Region; Segment Forecast, 2022 – 2030” Report at https://www.polarismarketresearch.com/industry-analysis/buccal-drug-delivery-system-market

The market primarily depends on the type, application, end-use, and region

Buccal drug delivery market: By type

  • Sublingual Films
  • Buccal Tablets and Lozenges
  • Oral Sprays

 

Buccal drug delivery market: By application

  • Pain Management
  • Smoking Cessation
  • Angina Pectoris
  • Others

 

Buccal drug delivery market: By end-use

  • Hospitals
  • Ambulatory Centers
  • Others

 

About Us:

Polaris Market Research is a worldwide market research and consulting organization. We give unmatched nature of offering to our customers present all around the globe across industry verticals. Polaris Market Research has expertise in giving deep-dive market insight and market intelligence to our customers spread crosswise over various undertakings. We at Polaris are obliged to serve our different client base present over the enterprises of medicinal services, healthcare, innovation, next-gen technologies, semiconductors, chemicals, automotive, and aerospace & defense, among different ventures, present globally.

Media Contact
Company Name: Polaris Market Research and Consulting
Contact Person: Likhil
Email: Send Email
Phone: +1-9292-97-97-27
Address:30 Wall Street 8th Floor, New York City, NY 10005, United States
City: New York City
State: US
Country: United States
Website: https://www.polarismarketresearch.com/industry-analysis/buccal-drug-delivery-system-market